Induction therapy: MRC UKALL XII/ECOG E2993
Phase and therapy . | Dosage . | Route of administration . | Days administered . |
|---|---|---|---|
| Phase 1, weeks 1-4 | |||
| Daunorubicin | 60 mg/m2 | IV | 1, 8, 15, 22 |
| Vincristine | 1.4 mg/m2 | IV | 1, 8, 15, 22 |
| l-asparaginase | 10 000 U | IV or IM | 17-28 |
| Prednisone | 60 mg/m2 | PO | 1-28 |
| Methotrexate | 12.5 mg | IT | 15 |
| Phase 2, weeks 5-8 | |||
| Cyclophosphamide | 650 mg/m2 | IV | 1, 15, 29 |
| Cytarabine | 75 mg/m2 | IV | 1-4, 8-11, 15-18, 22-25 |
| 6-Mercaptopurine | 6 mg/m2 | PO | 1-28 |
| Methotrexate | 12.5 mg | IT | 1, 8, 15, 22 |
Phase and therapy . | Dosage . | Route of administration . | Days administered . |
|---|---|---|---|
| Phase 1, weeks 1-4 | |||
| Daunorubicin | 60 mg/m2 | IV | 1, 8, 15, 22 |
| Vincristine | 1.4 mg/m2 | IV | 1, 8, 15, 22 |
| l-asparaginase | 10 000 U | IV or IM | 17-28 |
| Prednisone | 60 mg/m2 | PO | 1-28 |
| Methotrexate | 12.5 mg | IT | 15 |
| Phase 2, weeks 5-8 | |||
| Cyclophosphamide | 650 mg/m2 | IV | 1, 15, 29 |
| Cytarabine | 75 mg/m2 | IV | 1-4, 8-11, 15-18, 22-25 |
| 6-Mercaptopurine | 6 mg/m2 | PO | 1-28 |
| Methotrexate | 12.5 mg | IT | 1, 8, 15, 22 |
IV indicates intravenously; IM, intramuscularly; PO, by mouth; IT, intrathecally.